Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
12.70EUR
3.28 BEUR
8.91 BEUR
257.68 M
About Vertex Pharmaceuticals Incorporated
Sector
CEO
Reshma Kewalramani
Headquarters
Boston
Website
Employees (FY)
5.4 K
Founded
1989
FIGI
BBG01K3XDX56
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where 1VRTX is featured.
Frequently Asked Questions
The current price of 1VRTX is 374.15 EUR — it has increased by 0.99% in the past 24 hours. Watch VERTEX PHARMACEUTICALS stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange VERTEX PHARMACEUTICALS stocks are traded under the ticker 1VRTX.
VERTEX PHARMACEUTICALS is going to release the next earnings report on May 6, 2024. Keep track of upcoming events with our Earnings Calendar.
1VRTX stock is 0.98% volatile and has beta coefficient of 0.86. Track VERTEX PHARMACEUTICALS stock price on the chart and check out the list of the most volatile stocks — is VERTEX PHARMACEUTICALS there?
1VRTX earnings for the last quarter are 3.81 EUR per share, whereas the estimation was 3.68 EUR resulting in a 3.27% surprise. The estimated earnings for the next quarter are 3.78 EUR per share. See more details about VERTEX PHARMACEUTICALS earnings.
VERTEX PHARMACEUTICALS revenue for the last quarter amounts to 2.28 B EUR despite the estimated figure of 2.28 B EUR. In the next quarter revenue is expected to reach 2.39 B EUR.
Yes, you can track VERTEX PHARMACEUTICALS financials in yearly and quarterly reports right on TradingView.
1VRTX stock has risen by 1.20% compared to the previous week, the month change is a 0.21% fall, over the last year VERTEX PHARMACEUTICALS has showed a 8.37% increase.
1VRTX net income for the last quarter is 877.74 M EUR, while the quarter before that showed 979.39 M EUR of net income which accounts for −10.38% change. Track more VERTEX PHARMACEUTICALS financial stats to get the full picture.
Today VERTEX PHARMACEUTICALS has the market capitalization of 96.28 B, it has increased by 0.85% over the last week.
No, 1VRTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 1VRTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade VERTEX PHARMACEUTICALS stock right from TradingView charts — choose your broker and connect to your account.
1VRTX reached its all-time high on Jan 30, 2024 with the price of 428.10 EUR, and its all-time low was 318.15 EUR and was reached on Nov 17, 2023. View more price dynamics on 1VRTX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
As of May 6, 2024, the company has 5.40 K employees. See our rating of the largest employees — is VERTEX PHARMACEUTICALS on this list?
We've gathered analysts' opinions on VERTEX PHARMACEUTICALS future price: according to them, 1VRTX price has a max estimate of 536.84 EUR and a min estimate of 303.96 EUR. Watch 1VRTX chart and read a more detailed VERTEX PHARMACEUTICALS stock forecast: see what analysts think of VERTEX PHARMACEUTICALS and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. VERTEX PHARMACEUTICALS EBITDA is 3.58 B EUR, and current EBITDA margin is 45.32%. See more stats in VERTEX PHARMACEUTICALS financial statements.